Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind comparison of Viramidine vs ribavirin plus peginterferon alfa-2a in treatment-naïve chronic hepatitis C
2004-000408-41Phase 3Unknown
- Sponsor
- Ribapharm
- Start
- Feb 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of taribavirin in chronic hepatitis C (CHC) (2 arms), sponsored by Ribapharm. Primary endpoint: Hemoglobin safety endpoint. Status: unknown.
02
Drugs
taribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2004-000408-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000408-41.